Currently, we invest around £1bn in research and development (R&D) in the UK annually with our global R&D hub at Stevenage continuing to be at the heart of the development of our pipeline of vital medicines, with a focus on the immune system, genetics, and advanced technologies.
Our culture powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. We are recognised in the Stonewall LGBT+ rights group as a top global employer and ranked in the Times Top 50 employers for women in the UK.
We also support our global and local communities. £1.7m has been raised by UK employees for Save the Children so far, with 100% of these funds being used to help provide UK families living on low incomes with essential household items, learning resources, and support that gives parents the skills, confidence and tools to help their children thrive.
Members of the public in the UK can obtain information about our products and areas of therapy by visiting our
Our locations in the UK
Contact details
GSK HQ
79 New Oxford Street
London
United Kingdom
WC1A 1DG
UK Corporate
Tel: +44 (0)20 8047 5000
UK Commercial
Tel: +44 (0)20 8990 9000
Prescription medicines/customer support team
Email: customercontactuk@gsk.com
UK medical and safety information
Tel: 0800 221 441
For general media enquiries visit Global media contacts
We routinely monitor the safety of all our medicines and all adverse events should be reported to us and the Medicines and Healthcare products Regulatory Agency via their yellow card scheme. To report an adverse event, use our online Patient safety reporting form or email: uksafety@gsk.com or tel: 0800 221 441
Use the UK HR main number to contact the right team for information regarding benefits and employment related questions:
Email: UKIRL.ServiceHR@gsk.com
Tel: +44 (0)20 7660 6942
Healthcare professionals
Healthcare professionals (HCPs) in the UK can get information about our products and therapy areas by visiting GSKPro
As a healthcare company we regularly work with HCPs. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website. You can find more information on our disclosure of payments here.
UK patients, journalists and members of public
In line with ABPI Code, we disclose payments for certain contracted services made to UK patients, journalists and members of the public, on an aggregate basis.
Partnerships
Despite having some of the best people and research facilities, experience has shown us that we can achieve even more through strong partnerships.
These can be with the NHS, other companies, non-profit organisations and the academic world. In fact, it’s a key element in our business strategy, which helps us develop innovative new medicines and vaccines but also helps improve access to treatments and patient care
GSK-sponsored research projects
Discover GSK-sponsored research projects which explore healthcare challenges and opportunities. Here you will find relevant projects aimed at deepening understanding of key topics with the aim of helping to contribute towards improved patient outcomes.
The Office of Health Economics (OHE) explored the impact of pharmacy-based vaccination on health equity, plus the potential opportunities this creates for GPs, the NHS and the wider healthcare system. To do this, OHE observed three adult national immunisation programmes - influenza, shingles and pneumococcal.
Intended audience
Those with a role in Pharmacy and/or National immunisation programmes
Read GSK-sponsored Office of Health Economics report
NP-GB-ABX-WCNT-240010. November 2024
Joint working
We are actively involved in a wide number of joint working projects with the NHS throughout the UK. By working together we aim to improve the management of different conditions, introduce greater efficiency introduce greater efficiency and to achieve our ambition to unite science, technology and talent to get ahead of disease together.
The projects outlined below were undertaken over the last five years and, over this period, codes, regulations and laws governing the areas covered by the studies may have changed. When reading the documents please be assured that all projects followed the particular standards in force at the time even though these may have subsequently changed.
All of the featured case studies are intended to give an overview of the individual project including its background, the potential benefits for the patient, the NHS, GSK and any other stakeholders.
- Connected Inhaler Service Evaluation Project In The Routine Clinical Assessment Of Severe Asthma (PDF - 180.6KB)
- NHS Greater Glasgow and Clyde Health Board and GSK Joint Working project- ‘Care Optimisation in Greater Glasgow and Clyde’ (PDF - 130.3KB)
- Executive Summary UNITE Service Barts Health NHS Trust & The Royal Free London NHS Foundation Trust (PDF - 161.9KB)
- Executive Summary UNITE Service Hampshire And Isle Of Wight ICS (PDF - 169.6KB)
- Executive Summary UNITE Service Bedfordshire, Luton And Milton Keynes ICB & GSK (PDF - 168.8KB)
- Executive Summary GSK Bury GP Federation Collaborative Working Shingles NIP Improvement (PDF - 94.5KB)
- COPD Legacy Project Across Norfolk And Waveney (PDF - 121.7KB)
- East Kent Confed ICSJW Executive Summary (PDF - 119.2KB)
- GlaxoSmithKline (UK Ltd) and NHS Devon ICB COPD Joint Working Project Executive Summary (PDF - 172.6KB)
- Executive Summary GSK and Operose Health Collaborative Working Shingles NIP Quality Improvement Programme (PDF - 72.1KB)
- Executive Summary GSK Adult Immunisation Collaborative Working Project (PDF - 105.7KB)
- Executive Summary GSK and OurNet Health Services (Walsall) Adult Immunisation Collaborative Working Project (PDF - 131.7KB)
- Executive Summary GSK and Healthcare Central London Adult Immunisation Collaborative Working Project (PDF - 188.9KB)
- Executive Summary GSK and Healthbridge Direct Adult Immunisation Collaborative Working Project (PDF - 199.6KB)
- Executive Summary GSK and SSP Health Medical Services Adult Immunisation Collaborative Working Project (PDF - 189.2KB)
- Executive Summary GSK and Hartlepool & Stockton Health Adult Immunisation Collaborative Working Project (PDF - 136.2KB)
- Executive Summary GSK and Modality Adult Immunisation Collaborative Working Project (PDF - 133.7KB)
- Aneurin Bevan University Health Board Joint Working Summary Of Outcomes (PDF - 607.6KB)
- Black Country Summary Of Outcomes (PDF - 354.5KB)
- Greater Manchester Summary Of Outcomes (PDF - 443.8KB)
- Hampshire And Isle Of Wight ICB Joint Working Summary Of Outcomes (PDF - 485.2KB)
- Our Health Partnership COPD Project Summary Of Outcomes (PDF - 508.0KB)
- Frimley Health Foundation Trust Joint Working 2019-2020 Summary of project (PDF - 118.8KB)
- Summary of COPD risk stratification: Helping you to prioritise patients most in need Joint Working Project (GlaxoSmithKline (UK Ltd) and Frimley Health and Care Integrated Care System) 2021 – 2022 (PDF - 124.7KB)
- Bury GP Federation Collaborative Working Shingles NIP Outcomes Summary. (PDF - 261.2KB)
- Outcomes from the UNITE Service - Hull University Teaching Hospitals NHS Trust and GlaxoSmithKline UK Ltd (GSK) (PDF - 223.3KB)
- Summary of Outcomes of “Care optimisation in COPD service” Joint Working Project (GlaxoSmithKline (UK Ltd) and NHS Scottish Borders (PDF - 398.3KB)
- Bedfordshire, Luton and Milton Keynes Summary of Outcomes (PDF - 362.9KB)
- Sefton Place Summary of Outcomes (PDF - 485.3KB)
- Berkshire West of Summary of Outcomes (PDF - 365.9KB)
- Birmingham and Solihull ICB Joint Working Summary of Outcomes (PDF - 546.1KB)
Grants and donations
We recognise a responsibility to support activities in our medical community, whether related to medical education where there is patient need and common scientific interest, professional societies’ initiatives, or assisting healthcare organisations and projects that promote other healthcare goals. In all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
GSK UK’s Grants and Donations Committee uses the following criteria when assessing applications from Healthcare Organisations and Patient Advocacy Groups:
- The grant or donation must be used for an activity with a valid and legitimate purpose that enhances patient care, or benefits the NHS and maintains patient care. Programmes currently within scope for approval include:
- Patient Advocacy Group initiated Programmes and Core Funding
- Grants to organisations that support healthcare professionals and related staff to attend Scientific Congresses with decision-making independent of GSK
- Public policy and advocacy programs and initiatives, including legal reform and government relations
- The activity must be in a GSK disease area of strategic priority: Respiratory, Oncology, Specialty and COVID-19, Vaccines.
- Funding must be proportional to the activity and not excessive.
- Applications must be from a legitimate, reputable organisation that has the capability and licences to conduct the activity.
- The grant must be made in a manner that does not affect the independence of the recipient.
- A grant will only extend beyond one year under exceptional circumstances.
- A grant will not be given to an individual or be used for personal use.
- A grant cannot provide more than 25% of total funding received by a single recipient through GSK grants, except for rare disease or start-up patient groups, which can receive up to 50% of the total funding. Any exception requires additional approval and shall not exceed 50% in any case.
Please return your completed request form to gsk.grant-request@gsk.com. We will review qualifying grant requests and may reach out for additional information.
Carbon reduction plan
In accordance with UK Cabinet Office standards, the attachment below is GSK’s Carbon Reduction Plan completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.
